Gene · 8647
Papers3,310
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,310
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Intraduodenal fecal microbiota transplantation ameliorates gut atrophy and cholestasis in a novel parenteral nutrition piglet model. | Am J Physiol Gastrointest Liver Physiol | 2024 | 39163019 | PubTator, text mining | PubMed |
| The spectrum of novel ABCB11 gene variations in children with progressive familial intrahepatic cholestasis type 2 in Pakistani cohorts. | Sci Rep | 2024 | 39143102 | PubTator, text mining | PubMed |
| ABC transporters involved in respiratory and cholestatic diseases: From rare to very rare monogenic diseases. | Biochem Pharmacol | 2024 | 39111603 | PubTator, text mining | PubMed |
| Isoastragaloside I attenuates cholestatic liver diseases by ameliorating liver injury, regulating bile acid metabolism and restoring intestinal barrier. | J Ethnopharmacol | 2024 | 39094754 | PubTator, text mining | PubMed |
| Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury. | Int Immunopharmacol | 2024 | 39068755 | PubTator, text mining | PubMed |
| Cholesterol Allosterically Modulates the Structure and Dynamics of the Taurocholate Export Pump (ABCB11). | J Phys Chem Lett | 2024 | 39058973 | PubTator, text mining | PubMed |
| Emodin alleviates cholestatic liver injury by modulating Sirt1/Fxr signaling pathways. | Sci Rep | 2024 | 39033253 | PubTator, text mining | PubMed |
| Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters. | J Appl Toxicol | 2024 | 39030772 | PubTator, text mining | PubMed |
| Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways. | Toxicol Appl Pharmacol | 2024 | 39019095 | PubTator, text mining | PubMed |
| Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis. | Biomed Pharmacother | 2024 | 38889641 | PubTator, text mining | PubMed |
| Making assessment a team sport: a qualitative study of facilitated group feedback in internal medicine residency. | Can Med Educ J | 2024 | 38827914 | PubTator, text mining | PubMed |
| Oligomerization of drug transporters: Forms, functions, and mechanisms. | Acta Pharm Sin B | 2024 | 38799641 | PubTator, text mining | PubMed |
| Vincamine alleviates intrahepatic cholestasis in rats through modulation of NF-kB/PDGF/klf6/PPARγ and PI3K/Akt pathways. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | 38761209 | PubTator, text mining | PubMed |
| From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling. | Arch Toxicol | 2024 | 38755481 | PubTator, text mining | PubMed |
| A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction. | Toxicology | 2024 | 38740170 | PubTator, text mining | PubMed |
| Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Gastroenterol Hepatol | 2024 | 38723644 | PubTator, text mining | PubMed |
| Metabonomics and pharmacodynamics studies of Gentiana radix and wine-processed Gentiana radix in damp-heat jaundice syndrome rats. | J Ethnopharmacol | 2024 | 38705427 | PubTator, text mining | PubMed |
| A novel ABCB11 variant in compound heterozygosity: BRIC2 or PFIC2? | Gastroenterol Rep (Oxf) | 2024 | 38665279 | PubTator, text mining | PubMed |
| Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway. | J Ethnopharmacol | 2024 | 38663779 | PubTator, text mining | PubMed |
| A Rare Case of Benign Recurrent Intrahepatic Cholestasis Initially Diagnosed in Middle-age. | Altern Ther Health Med | 2024 | 38607191 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8647/papers?page=9